Related Experiment Video

Updated: Jul 19, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

Pulmonary hypertension in children: the twenty-first century

Stuart Berger1, Girija G Konduri

  • 1Medical College of Wisconsin, Children's Hospital of Wisconsin, 9000 West Wisconsin Avenue, Milwaukee, WI 53226, USA. sberger@mcw.edu

Pediatric Clinics of North America
|October 10, 2006
PubMed

Insights

Pulmonary hypertension (PH) involves elevated pulmonary artery pressure, impacting children with varied presentations. This review focuses on idiopathic pulmonary hypertension, discussing current medical therapies and future concepts for improved outcomes.

Area of Science:

  • Pediatric Cardiology
  • Pulmonology
  • Vascular Biology

Background:

  • Pulmonary hypertension (PH) is characterized by elevated pulmonary artery pressure, stemming from diverse underlying conditions.
  • Clinical manifestations and severity of PH are highly variable.
  • Recent advancements in understanding PH pathophysiology, genetics, and vascular biology have transformed the field.

Purpose of the Study:

  • To review the current understanding of pulmonary hypertension in pediatric populations.
  • To focus on idiopathic pulmonary hypertension (IPH), formerly primary pulmonary hypertension (PPH), in children.
  • To discuss medical therapies specifically for pediatric IPH and highlight broader therapeutic concepts for other PH causes.

Main Methods:

  • Literature review focusing on pediatric pulmonary hypertension.
  • Emphasis on idiopathic pulmonary hypertension and its treatment.
  • Inclusion of recent findings in pathophysiology and vascular biology.

Main Results:

  • Significant progress has been made in understanding the complex mechanisms of PH.
  • New medical interventions have emerged, leading to improved patient outcomes.
  • Idiopathic pulmonary hypertension in children remains a key focus for therapeutic development.

Conclusions:

  • Advances in PH research have led to improved therapeutic strategies, particularly for pediatric IPH.
  • Continued research into the pathophysiology and genetics of PH is crucial for developing novel treatments.
  • A comprehensive approach considering various causes of PH is essential for optimal patient management.

More Related Videos

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...